Lack of clinical therapeutic synergism between cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum(II) in metastatic human colorectal carcinoma.
Thirty patients with metastatic adenocarcinoma originating in the colon or rectum were treated with a combination of cyclophosphamide, Adriamycin, and cis-dichlorodiammineplatinum(II). Only one partial tumor regression of 12 weeks' duration was observed. Severe nausea and vomiting secondary to chemotherapy were frequently seen. This three-drug regimen, as employed in our study, was not associated with useful clinical activity against human metastatic colorectal cancer.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004359:Drug Therapy, Combination; D006801:Humans; D009325:Nausea / Q000139:chemically induced; D012004:Rectal Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin